

ASX RELEASE

Release of escrow shares from voluntary extension

Wellington, NZ, 12th April 2019: <u>Volpara Health Technologies</u> ("Volpara"; ASX: VHT), a medical technology company whose Al imaging algorithms assist the early detection of breast cancer, advises that 51,482,213 shares held by the founders and directors are due for release from voluntary escrow on 27th April 2019.

The end of the voluntary escrow periods marks three years of these shares being held in escrow since Volpara listed on the ASX in 2016. The founders and directors remain committed to the long-term success of Volpara.

ENDS.

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com t: +64 21 149 0541 Kyahn Williamson WE Buchan kwilliamson@we-buchan.com t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide software, VolparaEnterprise, provides role-specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 37 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand. For more information, visit www.volparasolutions.com.